DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
> Dexcom added the Ambulatory Glucose Profile report, developed by the International Diabetes Center, into its web-based Clarity platform in Europe. The AGP provides physicians and healthcare ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, announced today that it incorporated Ambulatory Glucose Profile ...
DexCom, Inc.DXCM recently launched its mobile application, CLARITY. Notably, Notably, this smart app is a cloud-based diabetes management software that simplifies CGM (Continuous Glucose Monitoring) ...
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has granted clearance to a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback